Johnson & Johnson to Participate in the Barclays Global HealthCare Conference Pharmaceutical Investing
Opdivo® in Combination with CABOMETYX® Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma Pharmaceutical Investing
Johnson & Johnson Appoints Dr. John Reed as Executive Vice President, Pharmaceuticals, R&D Pharmaceutical Investing
Seelos Therapeutics Announces Completion of Enrollment of its Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform Psychedelics Investing
Lobe Sciences, Ltd. Announces USD$250,000 Convertible Note Financing and Warrant Issuance Pharmaceutical Investing
Abecma Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3 KarMMa-3 Study Pharmaceutical Investing
